Internalizing anti-CD74 antibodies and methods of use

Details Internalizing anti-CD74 antibodies and methods of use Internalizing anti-CD74 antibodies and methods of use

2011-04-26

2011-04-26

Huff, Sheela J (Department: 1643)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C424S183100, C424S133100, C424S138100

Reexamination Certificate

active

07931903

ABSTRACT:
The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6306393 (2001-10-01), Goldenberg et al.
patent: 6653104 (2003-11-01), Goldenberg et al.
patent: 7312318 (2007-12-01), Hansen et al.
patent: 7585491 (2009-09-01), Govindan
patent: 2002/0018749 (2002-02-01), Hudson et al.
patent: 2002/0041847 (2002-04-01), Goldenberg
patent: 2003/0013122 (2003-01-01), Bucala et al.
patent: 98/50435 (1998-11-01), None
patent: 00/67795 (2000-11-01), None
patent: 00/74718 (2000-12-01), None
Bendig, M., “Humanization of Rodent Monoclonal Antibodies by CDR Grafting”, Academic Press Inc., New York, NY, vol. 8, (1995), pp. 83-93.
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue”, J. Cell Biol. 111:2129-2138 (1990).
Colman, P., “Effects of amino acid sequence changes on antibody-antigen interactions”, Res. Immunol. 1994, 145:33-36.
Gondo et al., “HLA class II antigen associated invariant chain gene expression in malignant lymphoma”, Br. J. Haematol. Dec. 1987;67(4):413-7.
Hansen et al., “Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas”, Biochem. J. 1996, 320:293-300.
Ibragimova et al., “Stability of the beta-sheet of the WW domain: A molecular dynamics simulation study”, Biophys. J. Oct. 1999;77(4):2191-8.
Kolata, G., “Clinical promise with new hormones”, Science 236:517-519 (1987).
Lazar et al., “Transforming growth factor alpha: an aromatic side chain at position 38 is essential for biological activity”, Mol. Cell. Biol. 8(3):1247-1252 (1988).
Leung et al., “Chimerization of LL2, a Rapidly Internalizing Antibody Specific for B Cell Lymphoma”, Hybridoma 13 (6):469-76 (1994).
Leung et al., “Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific leukemia/lymphoma antibody, LL2”, Mol. Immunol. 32(17/18):1413-1427 (1995).
Moller et al., “CD74”, J. Biol. Regul. Homeost. Agents Oct.-Dec. 2000;14(4):299-301.
Ochakovskaya et al., “Therapy of Disseminated B-Cell Lymphoma Xenografts in Severe Combined Immunodeficient Mice with an Anti-CD74 Antibody Conjugated with (111)Indium, (67)Gallium, or (90)Yttrium”, Clin. Cancer Res. 7(6):1505-1510 (2001).
Orlandi et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction”, Proc. Natl. Acad. Sci. USA 86:3833-3837 (1989).
Oster et al., “Erythropoietin for the Treatment of Anemia of Malignancy Associated with Neoplastic Bone Marrow Infiltration”, J. Clin. Oncol., 8(6):956-962 (1990).
Qu et al., “Internalization and Cytotoxic Effects of a Humanized Anti-CD74 Antibody, LL1”, Proc. Am. Assoc. Cancer Res 2002;43:255.
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”, Proc. Natl. Acad. Sci. USA 1982;79(6):1979-83.
Shih et al., “Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice”, Cancer Immunol. Immunother. 49:208-216 (2000).
Tutt et al., “Monoclonal Antibody Therapy of B Cell Lymphoma: Signaling Activity on Tumor Cells Appears More Important Than Recruitment of Effectors”, J. Immunol. 161(6):3176-85 (1998).

Affiliated with

Also associated with

Rating

Internalizing anti-CD74 antibodies and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Internalizing anti-CD74 antibodies and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Internalizing anti-CD74 antibodies and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2685383